Interestingly, a greater proportion of these models (five out of eight) were insensitive against a standard of care treatment based on their initial characterization in the EPO tumor biobank and therefore classified as highly resistant tumors with progressive disease (PD) as response according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria21 within the PDX panel. Here, EPO is linked to neoplasm.